Canadian regulator OKs Hugel's botulinum toxin product

Korea Biomedical Review

16 June 2022 - Hugel said Thursday that it has obtained product approval from Health Canada for its botulinum toxin formulation, Letybo, which treats forehead wrinkles.

The company had completed an on-site inspection of the Geodu plant, Hugel's botulinum toxin production base, to obtain a Canadian product license in November 2019 and applied for a product license on 1 July 2021.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada